NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well ...
With this information in hand, researchers who, for instance, are developing a gene therapy to treat a muscle condition, could use the atlas to identify AAV vectors that preferentially target the ...
Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...
Lexeo Therapeutics (NASDAQ:LXEO) executives outlined the company’s focus on precision medicines for inherited cardiac diseases during a presentation at Oppenheimer’s 36th Annual Healthcare Life ...
VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology ...
Non-human primate study results demonstrate improvements in skeletal and cardiac muscle delivery efficacy, safety potential, human translatability, and manufacturability over prior AAV capsids ...
Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in a cohort of patients who had been ...
Gene Therapy Meets Regulatory Reality: The FDA–uniQure Clash Over a Promising Huntington’s Treatment
The FDA’s dispute with biotech firm uniQure over Huntington’s gene therapy highlights growing tensions between innovation, ...
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results